Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Assisted Reproduction and Genetics
Erschienen in:

03.08.2020 | COVID-19 | Commentary Zur Zeit gratis

Cryopreservation and IVF in the time of Covid-19: what is the best good tissue practice (GTP)?

verfasst von: Kimball O. Pomeroy, Mitchel C. Schiewe

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Examine good tissue practices as relates to in vitro fertilization, biopsying, and vitrificationto compare current knowledge of ova, sperm, and embryos as vectors for disease transmission as it relates to our current knowledge regarding the SARS-CoV-2 virus.
Unknown risks relating to the SARS-CoV-2 virus and sperm, ova, and embryos necessitate a reexamining of how human IVF is performed. Over the last decade, improvements in cryosurvival and live birth outcomes have been associated with zona pellucida breaching procedures (e.g., blastocyst collapsing and biopsying). In turn, today embryos are generally no longer protected by an intact zona pellucida when vitrified and in cryostorage. Additionally, high security storage containers have proven to be resilient to potential cross-contamination and reliable for routine human sperm freezing and embryo vitrification.
Several options to current IVF practices are presented that can effectively mitigate the risks of cross-contamination and infection due to the current Covid-19 pandemic or other viral exposures. The question remains; is heightened security and change warranted where the risks of disease transmission likely remain negligible?
Literatur
1.
Pomeroy K, Harris S, Conaghan J, Papadakis M, Centola G, Basuray R, et al. Storage of cryopreserved reproductive tissues: evidence that cross-contamination of infectious agents is a negligible risk. Fertil Steril. 2010;94(4):1181–8.CrossRef
2.
3.
4.
5.
Prussin A II, Marr LC. Source of airborne microorganisms in the built environment. Microbiome. 2015;3:78–88.CrossRef
6.
Qian J, Hospodsky D, Yamamoto N, Nazaroff W, Peccia J. Size-resolved emission rates of airborne bacteria and fungi in an occupied classroom. Indoor Air. 2012;22:339–51.CrossRef
7.
Bielanski A. A review of the risk of contamination of semen and embryos during cryopreservation and measures to limit cross-contamination during banking to prevent disease transmission in ET practices. Theriogenology. 2012;77(3):467–82.CrossRef
8.
9.
Hema N, Raj N, Chaithanya E, Chincholi R, Iswariya M, Hema K. J. Oral Maxi Prevalence of nasal carriers of methicillin-resistant Staphylococcus aureus among dental students: an in vivo study. J Oral Maxillofac Pathol. 2017;21(3):356–9.CrossRef
10.
11.
12.
Holtmann N, Edimiris P, Andree M, Doehmen C, Baston-Buest D, Adams O, et al. Assessment of SARS-CoV-2 in human semen - a cohort study. Fertil Steril. In Press.
13.
Pan F, Xiao X, Guo J, Song Y, Li H, Patel D, et al. No evidence of SARS-CoV-2 in 393 semen of males recovering from COVID-19. Fertil Steril. 2020;113(6):1135–9.CrossRef
14.
Araneta M, Mascola L, Eller A, O'Neil L, Ginsberg M, Bursaw M, et al. HIV transmission through donor artificial insemination. JAMA. 1995;273(11):854–8.CrossRef
15.
Quayle A, Zu C, Mayer K, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis. 1997;176:960–8.CrossRef
16.
Loskutoff N, Huyser C, Singh R, Tech B, Walker D, Thornhill A, et al. Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. Fertil Steril. 2005;84:1001–10.CrossRef
17.
Dineen T, Woodward B. Other factors to consider with sperm preparation for treatment. In: Jayant Mehta BW, editor. Male infertility: sperm diagnosis, management and delivery. JP Medical Publishers, Ltd: London; 2014. p. 71–80.
18.
Givens D, Stringfellow DA. Manual of the International Embryo Transfer Society: a procedural guide and general information for the use of embryo transfer technology, emphasizing sanitary precautions. 4th ed. Champaign: International Embryo Transfer Society; 2008. p. 1–145.
19.
20.
Parmegiani L, Accorsi A, Cognigni G, Bernardi S, Troilo E, Filicori M. Sterilization of liquid nitrogen with ultraviolet irradiation for safe vitrification of human oocytes or embryos. Fertil Steril. 2010;94(4):1525–8.CrossRef
21.
Parmegiani L, Accorsi A, Bernardi S, Arnone A, Cognigni G, Filicori M. A reliable procedure for decontamination before thawing of human specimens cryostored in liquid nitrogen: three washes with sterile liquid nitrogen (SLN2). Fertil Steril. 2012;98(4):870–5.CrossRef
22.
Bielanski A, Dubuc C. In vitro fertilization of ova from cows experimentally infected with a non-cytopathic strain of bovine viral diarrhea virus. Anim Reprod Sci. 1995;38:215–22.CrossRef
23.
Cobo A, Bellver J, de los Santos M, Remohí J. Viral screening of spent culture media and liquid nitrogen samples of oocytes and embryos from hepatitis B, hepatitis C, and human immunodeficiency virus chronically infected women undergoing in vitro fertilization cycles. Fertil Steril. 2012;97(1):74–8.CrossRef
24.
Tedder R, Zuckerman M, Goldstone A, Hawkins A, Fielding A, Briggs E, et al. Hepatitis B transmission from a contaminated cryopreservation tank. Lancet. 1995;346:137–40.CrossRef
25.
Bielanski A, Nadin-Davis S, Sapp T, Lutz-Wallace C. Viral contamination of embryos cryopreserved in liquid nitrogen. Cryobiology. 2000;40(2):110–6.CrossRef
26.
Kyuwa S, Nishikawa T, Kaneko T, Nakashima T, Kawano K, Nakamura N, et al. Experimental evaluation of cross-contamination between cryotubes containing mouse 2-cell embryos and murine pathogens in liquid nitrogen tanks. Exp Anim. 2003;52(1):67–70.CrossRef
27.
Van Landuyt L, Verpoest W, Verheyen G, De Vos A, Van de Velde H, Liebaers I, et al. Closed blastocyst vitrification of biopsied embryos: evaluation of 100 consecutive warming cycles. Hum Reprod. 2010;26:316–22.CrossRef
28.
Schiewe MC, Zozula S, Anderson RE, Fahy GM. Validation of microSecure vitrification (μS-VTF) for the effective cryopreservation of human embryos and oocytes. Cryobiology. 2015;71:264–72.CrossRef
29.
Schiewe MC, Zozula S, Nugent N, Waggoner K, Borba J, Gamboa L, et al. Modified microSecure vitrification: a safe, simple and highly effective cryopreservation procedure for human blastocysts. J Vis Exp. 2017;121:e54871.
30.
Panagiotidis Y, Vanderzwalmen P, Prapas Y, Kasapi E, Goudakou M, Papatheodorou A, et al. Open versus closed vitrification of blastocysts from an oocyte-donation programme: a prospective randomized study. Reprod BioMed Online. 2013;26:470–6.CrossRef
31.
Papatheodorou A, Vanderzwalmen P, Panagiotidis Y, Prapas N, Zikopoulos K, Georgiou I, et al. Open versus closed oocyte vitrification system: a prospective randomized study. Reprod BioMed Online. 2013;26:595–602.CrossRef
32.
Wirleitner B, Vanderzwalmen P, Bach M, Baramsai B, Neyer A, Schwerda D, et al. The time aspect in storing vitrified blastocysts: its impact on survival rate, implantation potential and babies born. Hum Reprod. 2013;28:2950–7.CrossRef
33.
Mortimer D. Current and future concepts and practices in human sperm cryobanking. Reprod BioMed Online. 2004;9(2):134–51.CrossRef
34.
Anderson R, Whitney J, Schiewe M. Clinical benefits of preimplantation genetic testing for aneuploidy (PGT-A) for all in vitro fertilization treatment cycles. J Eur Med Genet. 2019;62:103731.
35.
Practice Committee of the American Society for Reproductive Medicine and The Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy (PGT-A: a committee opinion). Fertil Steril. 2018;109(3):429–36.CrossRef
Metadaten
Titel
Cryopreservation and IVF in the time of Covid-19: what is the best good tissue practice (GTP)?
verfasst von
Kimball O. Pomeroy
Mitchel C. Schiewe
Publikationsdatum
03.08.2020
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 10/2020
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-020-01904-5

Weitere Artikel der Ausgabe 10/2020

Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing

  • Genetics

What artificial intelligence may, or may not, contribute to human ARTs

  • Commentary

Timing day-3 vitrification for PGT-M embryos: pre- or post-blastomere biopsy?

  • Assisted Reproduction Technologies

Novel variants in women with premature ovarian function decline identified via whole-exome sequencing

  • Genetics

Assessing and validating housekeeping genes in normal, cancerous, and polycystic human ovaries

  • Reproductive Physiology and Disease

Ethical issues involving fertility preservation for transgender youth

  • Fertility Preservation

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält Brusttumoren langfristig in Schach

Erreichen Frauen mit HER2-positivem Mammakarzinom nach einer neoadjuvanten Therapie keine Komplettremission, bietet eine Therapie mit Trastuzumab Emtansin langfristig Vorteile: Die Sterberate ist im Vergleich zu einer Trastuzumab-Therapie um ein Drittel reduziert.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise